Measurement of airways hyperresponsiveness by mannitol (Aridol©) as compared to methacholine saves time to the lung function technician, while being as sensitive to discern hyperresponsive from normo-responsive, and being at least equally acceptable…
ID
Bron
Verkorte titel
Aandoening
Asthma, COPD, subjects without airways hyperresponsiveness
Ondersteuning
University Medical Center Groningen
Postbox 30.001
9700RB Groningen
the Netherlands
2/10 Rodborough Rd, Frenchs Forest NSW 2086
Australia
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Time involved in measurement of hyperresponsiveness (including technician time for preparation and cleaning).
Achtergrond van het onderzoek
Airway hyperresponsiveness (AHR) can be measured with direct (histamine or methacholine) and indirect agents (AMP, hypertonic saline, excercise and mannitol). We believe that measurement of airways hyperresponsiveness by mannitol (Aridol©) as compared to methacholine saves time to the lung function technician, while being as sensitive to discern hyperresponsive from normo-responsive. We will assess the saved time in this randomised, single-blinded, cross-over study.
Doel van het onderzoek
Measurement of airways hyperresponsiveness by mannitol (Aridol©) as compared to methacholine saves time to the lung function technician, while being as sensitive to discern hyperresponsive from normo-responsive, and being at least equally acceptable to patients presenting at a pulmonary out-patient clinic.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
Measurement of bronchial hyperresponsiveness with mannitol and methacholine.
Publiek
Department of Respiratory Medicine
Hanzeplein 1
Postbox 30.001
E.D. Telenga
Groningen 9700 RB
The Netherlands
+31 (0)50 3619505
E.D.Telenga@int.umcg.nl
Wetenschappelijk
Department of Respiratory Medicine
Hanzeplein 1
Postbox 30.001
E.D. Telenga
Groningen 9700 RB
The Netherlands
+31 (0)50 3619505
E.D.Telenga@int.umcg.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Asthmatics:
1. Episodic symptoms of dyspnea, and/or wheezing, and/or cough.
2. Allergic or non-allergic.
3. non current smokers (> 0.5 years).
4. PC20 MCh < 8 mg/ml
COPD patients:
1. Age > 40 yrs.
2. Active or former smokers, with a smoking history of more than 10 packyears.
3. Continuous symptoms of cough/sputum and/or dyspnea on exertion.
4. No history of asthma.
5. FEV1/FVC < 70 % and FEV1 between 50 and 80 % pred.
Controls:
1. No history of asthma or COPD;
2. PC20 MCh > 8 mg/ml;
3. FEV1/FVC > 70 % and FEV1 > 90 %pred.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Age < 18 years.
2. Inability to perform acceptable-quality spirometry or to understand directions given by personnel.
3. Severe airflow limitation (FEV1 < 50% of predicted or < 1.0 L).
4. Heart attack or stroke in last 3 months.
5. Uncontrolled hypertension, systolic BP > 200, or diastolic BP > 100.
6. Known aortic aneurysm.
7. Pregnancy.
8. Nursing mothers.
9. Current use of cholinesterase inhibitor medication (for myasthenia gravis).
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL746 |
| NTR-old | NTR756 |
| Ander register | : Griac001 |
| ISRCTN | ISRCTN72604310 |